2023 World Conference on Lung Cancer (Posters)-EP08.01. Single-Cell RNA Sequencing Reveals Unique Immune Landscape in Rare-Mutant Non-Small Cell Lung Cancer Undergoing Chemo-Immunotherapy

EP08.01. Single-Cell RNA Sequencing Reveals Unique Immune Landscape in Rare-Mutant Non-Small Cell Lung Cancer Undergoing Chemo-Immunotherapy - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the WCLC 2023 conference revealed findings from single-cell RNA sequencing on nine non-small cell lung cancer (NSCLC) specimens with rare mutations. The study aimed to understand the immune landscape and response patterns of NSCLC patients with rare mutations undergoing chemo-immunotherapy. The results showed that patients with a major pathological response (MPR) had higher levels of infiltrating T cells and natural killer cells compared to those without MPR. However, the distribution of cell types varied among different rare driver mutations. The study also found that patients with the BRAF V600E mutation and MPR exhibited enrichment of IGHG plasma cells, while myeloid cells, particularly macrophages, had profibrotic gene enrichment in BRAF V600E patients without MPR. Patients with ERBB2 mutations showed differential expression of immune cell markers based on residual tumor percentage. Additionally, FGFBP2 NK cells were enriched in patients with KIF5B-RET fusions who achieved a pathological complete response. These findings provide insights into the unique immune landscape at the single-cell level in rare-mutant NSCLC undergoing chemo-immunotherapy. The study suggests that these findings could aid in the development of personalized therapeutic strategies for locally advanced NSCLC patients with rare mutations.

Asset Subtitle

Rui Fu

Meta Tag

Speaker Rui Fu

Topic Local-Regional NSCLC: Biomarkers

Keywords

WCLC 2023 conference

single-cell RNA sequencing

NSCLC

rare mutations

chemo-immunotherapy

pathological response

T cells

BRAF V600E mutation

myeloid cells

FGFBP2 NK cells